Canada - English - Health Canada

sanis health inc - warfarin sodium - tablet - 2mg - warfarin sodium 2mg - coumarin derivatives

Canada - English - Health Canada

sanis health inc - warfarin sodium - tablet - 2.5mg - warfarin sodium 2.5mg - coumarin derivatives

Canada - English - Health Canada

sanis health inc - warfarin sodium - tablet - 3mg - warfarin sodium 3mg - coumarin derivatives

Canada - English - Health Canada

sanis health inc - warfarin sodium - tablet - 4mg - warfarin sodium 4mg - coumarin derivatives

Canada - English - Health Canada

sanis health inc - warfarin sodium - tablet - 5mg - warfarin sodium 5mg - coumarin derivatives

Canada - English - Health Canada

sanis health inc - warfarin sodium - tablet - 6mg - warfarin sodium 6mg - coumarin derivatives

Canada - English - Health Canada

sanis health inc - warfarin sodium - tablet - 7.5mg - warfarin sodium 7.5mg - coumarin derivatives

Canada - English - Health Canada

sanis health inc - warfarin sodium - tablet - 10mg - warfarin sodium 10mg - coumarin derivatives

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; hypromellose; macrogol 400 - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effects may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and / or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis,/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - azathioprine -